课题基金 / 基金详情

The development of novel treatment through the hepatocellular carcinoma (HCC) specific siginaling pathway and molecular based gene expression profiling for advanced HCC

The development of novel treatment through the hepatocellular carcinoma (HCC) specific siginaling pathway and molecular based gene expression profiling for advanced HCC
通过肝细胞癌 (HCC) 特异性信号通路和基于分子的基因表达谱治疗晚期 HCC 的新型治疗方法的开发
批准号:
17390367
负责人:
UMESHITA Koji
金额:
$9.47万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2006

项目摘要

项目成果

UMESHITA Koji的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1) The mechanism of the antitumor effect through the IFN-IFNAR signalingThe anti-tumor effect of IFN/5-FU combined therapy was significantly correlated with the strength of IFNAR expression, in the HCC cells in-vitro. In this mechanism, the methylation of IFNAR gene was significantly correlated with anti-tumor effect, among the several factors.2) Anti tumor effect through the relationship between IFN and 5FU metabolismIn the anti-tumor effect of IFN and 5FU, IFN would induce the TS-1 inhibitory rate in 5FU metabolism.3) Anti tumor effect through Fas/FasLAmong peripheral blood cells, NK cells were found to exert the cytotoxic effects on human hepatoma cells. In addition, the involvement of CTL system in the anti tumor effect was examined and confirmed in terms of the relationship of apoptosis in this study.4) Anti tumor effect through the anti-angiogenic actionAbout the anti-angiogenic action of IFN, Ang-2 was the one of most important factor, among several anti-angiogenic molecules, TSP, Ang-1, VEGF, Tie2, HIF1-α.5) The Gene Expression ProfilingUsing the clinical samples treated by IFN-α and 5-FU, the gene expression profiling would be suggested to be useful for the prediction of the treatment efficacy at the over 85%.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3892/ijo.26.2.319
发表时间: 2005-02
期刊: International journal of oncology
影响因子: 5.2
作者: [B. Damdinsuren;H. Nagano;M. Kondo;Hirofumi Yamamoto;N. Hiraoka;Tameyoshi Yamamoto;S. Marubashi;A. Miyamoto;K. Umeshita;K. Dono;S. Nakamori;K. Wakasa;M. Sakon;M. Monden]
通讯作者: B. Damdinsuren;H. Nagano;M. Kondo;Hirofumi Yamamoto;N. Hiraoka;Tameyoshi Yamamoto;S. Marubashi;A. Miyamoto;K. Umeshita;K. Dono;S. Nakamori;K. Wakasa;M. Sakon;M. Monden
Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma : a comparative study with hepatocellular carcinoma and cholangiocellular carcinom.
切除的混合型肝细胞癌和胆管细胞癌的 Allen C 型分类的临床和病理特征:肝细胞癌和胆管细胞癌的比较研究。
DOI: --
发表时间: 2006
期刊: J Gastronitest Surg 2006 10(7)
影响因子: --
作者: [Tang D., Nagano H., Nakamura M., Wada H., Marubashi S., Miyamoto A., Takeda Y., Umeshita K., Dono K., Monden M.]
通讯作者: Monden M.
TGF-betal-induced cell growth arrest and partial differentiation is related to the suppression of Idl in human hepatoma cells.
TGF-β诱导的细胞生长停滞和部分分化与人肝癌细胞中Idl的抑制有关。
DOI: --
发表时间: 2006
期刊: Oncol Rep 15(2)
影响因子: --
作者: [Damdinsuren B., Nagano H., Kondo M., Natsag J., Hanada H., Nakamura M., Wada H., Kato H., Marubashi S., Miyamoto A., Takeda Y., Umeshita K., Dono K., Monden M.]
通讯作者: Monden M.
DOI: --
发表时间: 2005
期刊: 消化器科 40(6)
影响因子: --
作者: [永野浩昭, 門田守人]
通讯作者: 門田守人
27
    Suppression of hepatic ischemia/reperfusion injury by early expression of protective protein
    • 批准号:
      15591404
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.18万
    • 财政年份:
      2003
    • 负责人:
      UMESHITA Koji
    • 依托单位:
    Suppression of hepatic ischemia/reperfusion injury using RNA
    • 批准号:
      13671304
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.24万
    • 财政年份:
      2001
    • 负责人:
      UMESHITA Koji
    • 依托单位:
    海外基金